CLINIC MARKET INTELLIGENCE · UPDATED JUNE 2026 · UKMC GROUP LTD
Verified analysis of the UK medical cannabis clinic market for investors, family offices and private wealth owners — covering clinic economics, revenue models, patient retention, the leading operators, M&A dynamics and what regulatory change means for clinic valuations.
Published for informational purposes only. Does not constitute financial, legal, investment or regulatory advice. All data sourced from primary regulatory, corporate and verified press sources. Readers should seek independent professional advice before making any investment decision.
THE MARKET
Private clinics providing medical cannabis treatment in the UK as of early 2026. Source: Prohibition Partners Global Medical Cannabis Market Review 2026.
Specialist cannabis clinics actively prescribing as a primary activity. The remainder are general private clinics offering cannabis as one of several services. Source: Prohibition Partners 2026.
Active UK medical cannabis patients in 2025. Source: Prohibition Partners Global Medical Cannabis Market Review 2026.
Year-on-year UK market growth in 2025. Source: Prohibition Partners 2026.
UK medical cannabis market value in 2025. Source: Prohibition Partners 2026.
Share of UK medical cannabis prescriptions issued in independent private healthcare settings in 2024. Source: CQC 2025.
The UK medical cannabis clinic sector is the primary access point for the entire UK market. Unlike Germany — where any doctor can prescribe via standard e-prescription, or Australia — where integrated telemedicine platforms handle the majority of the market, the UK market flows almost entirely through a network of specialist private clinics, the majority of which offer telemedicine consultations as their primary or sole channel.
As of early 2026, the clinic network ranges from established multi-site operations with vertically integrated supply chains, to lean digital-first teleclinics, to general private healthcare providers that have added cannabis prescribing to a broader clinical offering. This heterogeneity is both a market characteristic and an investment risk — the clinical, compliance and financial profiles of individual clinic operators vary significantly, and the ACMD review is likely to accelerate differentiation between well-governed and poorly-governed operators.
THE OPERATORS
Releaf is the largest UK medical cannabis clinic by website traffic, recording 535,400 visits in October 2025 — the highest of any UK medical cannabis clinic. As of March 2026, Releaf had over 25,000 active patients and over £38 million in revenue. In January 2026, Releaf launched Releaf Protect — a subscription legal guidance helpline for UK medical cannabis patients — in a joint initiative with law firm Irwin Mitchell. Releaf operates a monthly subscription model called Releaf+, offering unlimited clinical access, discounted medication rates and other member benefits. The subscription model creates high patient retention and predictable recurring revenue — the most attractive financial characteristic from an investor perspective.
Source: Wikipedia (Releaf), Prohibition Partners 2026, SimilarWeb October 2025.
Curaleaf Clinic was named Cannabis Clinic of the Year 2024 and is rated the highest of any UK medical cannabis clinic in that award category. Sapphire Medical Clinics was acquired by Curaleaf International — Europe's largest vertically integrated medical cannabis company — creating a prescriber-to-supplier pipeline that is the most complete vertical integration in the UK market. Curaleaf Clinic recorded 301,138 website visits in October 2025 — the second-highest among UK clinics. The Curaleaf model combines prescription generation with proprietary product supply, creating a closed-loop economics structure that maximises margin capture across the value chain.
Source: Prohibition Partners 2026, SimilarWeb October 2025.
Alternaleaf recorded 157,008 website visits in October 2025 — the third highest in the UK market. Alternaleaf is part of the Australian vertically integrated operator Montu — one of the dominant players in the Australian medical cannabis market, where Alternaleaf/Montu's main platform attracted 212,959 website visits in October 2025. The UK operation brings the Montu model to the British market — leveraging the platform's existing technology infrastructure, clinical protocols and supply relationships.
Source: Prohibition Partners 2026, SimilarWeb October 2025.
Mamedica raised a £4.5 million funding round in September 2025 led by Casa Verde — the US-based cannabis-focused venture capital firm whose portfolio includes Dutchie, Metrc and Leaflink in the United States, and European positions in Cansativa and Sanity Group. Karan Wadhera, Managing Partner of Casa Verde, described Mamedica as a platform for the UK market's rapid growth phase. Mamedica has treated over 10,000 patients since inception, with approximately 7,500 actively under care as of the funding announcement, and around 10% month-on-month growth in initial consultations. The company recorded 1,250% patient growth in 2023 and 154% in 2024, and forecasts annual doubling of patient numbers. Mamedica operates a low-frequency clinical contact model — the initial consultation costs £150, with clinic fees dropping to £75 annually from year two — making it the lowest long-term consultation cost model in the UK market.
Source: Mamedica press release September 2025, Morningstar, Yahoo Finance.
Lyphe was acquired by Tilray — the Canadian cannabis company — creating the UK operating entity Tilray Lyphe UK Ltd. The Tilray acquisition represents one of the largest international strategic entries into the UK clinical market, connecting Canadian supply infrastructure directly to UK prescribing capacity. Lyphe recorded 74,822 website visits in October 2025.
Source: Prohibition Partners 2026, SimilarWeb October 2025.
The remaining active specialist clinics form a long tail of smaller operators, each with specific clinical specialities, prescriber networks or patient demographics. CB1 Medical recorded 26,858 visits, Integro Clinics 25,049, Ghosh Medical 14,291, Leva Clinic 9,569 and Treat-It 8,708 in October 2025.
Source: SimilarWeb, Prohibition Partners 2026.
REVENUE MODELS
Understanding how UK medical cannabis clinics generate and retain revenue is fundamental to evaluating them as investment targets. Three distinct models have emerged in 2026:
Monthly subscription fee covering unlimited clinical consultations, discounted medication rates and additional member benefits. Creates predictable recurring revenue, strong patient retention and high lifetime value per patient. Most attractive financial model from an investor perspective. Risk: subscription cancellation rates and patient churn are the key variables; subscriptions are contingent on patients continuing their treatment.
Higher upfront consultation fee (£150 initial consultation) with low ongoing clinical contact fees (£75 annually from year two). Repeat prescriptions are free and unlimited. Low friction for long-term patients, but lower recurring revenue per patient than the subscription model. Attracts cost-sensitive patients with stable, long-term conditions. Risk: revenue is more variable and depends heavily on patient volume growth.
Combines clinic revenue with proprietary product supply revenue. The clinic generates prescription volume, which flows to Curaleaf-supplied products through a pharmacy network. Margin is captured at both the consultation stage and the product supply stage. Most complex model but highest potential revenue per patient if supply relationships are maintained. Risk: CQC and regulatory scrutiny of closed-loop prescribing models — Australia's AHPRA flagged similar models as creating prescribing conflicts of interest in 2025.
M&A & INVESTMENT
The UK medical cannabis clinic sector is in an active investment and M&A phase. The combination of 103% year-on-year market growth, 90,000–94,000 active patients with significant room to grow toward the 1–2% patient penetration seen in comparable markets, and a comparatively defensible regulatory environment has attracted a range of investor types.
September 2025
Led by Casa Verde (Karan Wadhera, Managing Partner), whose portfolio includes Dutchie, Metrc and Leaflink in the US and Cansativa and Sanity Group in Europe. The round positions Mamedica to support up to 100,000 patients and to scale its proprietary digital healthcare platform.
Source: Mamedica press release, PR Newswire, September 2025.
January 2026
A subscription legal guidance helpline for UK medical cannabis patients — signalling Releaf's move beyond pure clinical services into patient lifecycle management and adjacent revenue streams.
Source: Wikipedia (Releaf), January 2026.
Ongoing
Tilray's acquisition of Lyphe represents the most significant international strategic entry into the UK clinic market — connecting a major Canadian licensed producer directly to UK prescribing infrastructure. The deal signals that Canadian producers are now pursuing downstream integration into patient-facing UK clinic assets as a supply chain strategy, not just export relationships.
WHAT INVESTORS ARE TARGETING
Family offices and private equity firms active in European cannabis M&A in 2026 are targeting asset-light, profitable operators with well-established pharmacy and prescriber relationships, extensive patient behaviour data and a trusted brand reputation. Those at the top of the M&A target list are operators with formulary presence — consistent CBPM prescribing driven by physician familiarity and clinical data rather than promotional spend alone.
Source: Business of Cannabis, Berlin 2026 ICBC M&A session, April 2026.
INVESTMENT RISKS
The ACMD review could recommend mandatory in-person initial consultations, stricter prescribing criteria or tighter advertising restrictions. Any of these changes would materially impact clinic revenue, patient acquisition costs and operating model viability. Digital-only clinics without physical infrastructure face higher exposure under any restriction scenario.
A clinic receiving a 'Requires Improvement' or 'Inadequate' CQC inspection rating faces immediate reputational damage, potential enforcement action and restriction on registrations. Patient attrition following a poor CQC rating can be severe and swift. Investors should conduct thorough CQC compliance due diligence on any target clinic.
Most UK clinics depend on a small number of GPhC-registered pharmacies to dispense CBPMs. The October 2025 GPhC inspection found that seven out of 25 inspected pharmacies failed governance standards. Any pharmacy losing its CBPM dispensing licence is a material event for the clinic networks it serves. Investors should map pharmacy dependency and dispensing concentration risk in any target clinic.
The UK market has a total number of prescribing doctors in the low hundreds. GMC-registered specialist prescribers with cannabis medicine CPD and clinical experience are scarce. Loss of key prescribers — through retirement, regulatory action or competitor poaching — is a material operational risk for clinic operators. Investors should assess prescriber concentration, contractual protections and pipeline recruitment.
Vertically integrated clinic models — where the same corporate group controls the clinic, the pharmacy and the product supply — face specific CQC and regulatory scrutiny regarding conflicts of interest in prescribing. Australia's AHPRA flagged this model explicitly in 2025. UK regulators are likely to assess similar models as part of the ACMD review process.
THE SUMMIT
The UK Medical Cannabis Investment Summit 2027 brings together clinic operators, investors, family offices, policymakers and clinicians to discuss the developments — including the ACMD review outcome — that will define UK medical cannabis clinic valuations in 2027 and beyond. Two days. London. June 2027.
FREQUENTLY ASKED QUESTIONS
IMPORTANT NOTICE: This page is published by UKMC Group Ltd for informational purposes only. Nothing on this page constitutes financial, investment, legal or regulatory advice. All data is sourced from primary regulatory, corporate and verified press sources as cited throughout. Market and regulatory conditions change — readers should verify current information independently and seek qualified professional advice before making any investment decision. © 2026 UKMC Group Ltd.